Clinical trials: Mild Alzheimer Disease
Healthy, Alzheimer Disease
First in Human Study for Safety and Tolerability of AL003.
This is a multi-center, randomized, double-blind, placebo-controlled, dose escalation first in human (FIH) study in healthy adults and in patients with mild to moderate Alzheimer's disease.
- Trial name
- NCT03822208
- Testing
- AL003, Saline Solution
- Where
- 6 sites in United States, Australia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Alector Inc.
Mild Alzheimer's Disease
WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease
This is a double- blind, randomized controlled trial with an open label extension designed to evaluate the safety and potential efficacy of a non-invasive brainstem neuromodulation device for treating symptoms associated with…
- Trial name
- WAVE-AD (NCT05032482)
- Testing
- Non-invasive brainstem stimulation
- Where
- 5 sites in United States
- Sponsor
- Scion NeuroStim
Alzheimer Disease
A Study of Crenezumab in Participants With Mild to Moderate Alzheimer Disease
This randomized, placebo-controlled, double-blind, parallel-arm study will evaluate the safety and tolerability of at least two dose levels of intravenous (IV) crenezumab in 24-72 participants with mild to moderate Alzheimer…
- Trial name
- NCT02353598
- Testing
- Crenezumab dose level 1, Crenezumab dose level 2, Crenezumb dose level 3
- Where
- 13 sites in United States
- Volunteers
- 77 people
- Sponsor
- Genentech, Inc.
Mild Alzheimer's Disease, Amnestic Mild Cognitive Impairment
Effect of AQW051 in Patients With Memory Impairment
This study will investigate AQW051 in patients with either mild Alzheimer's disease or amnestic mild cognitive impairment. The effect on cognitive impairment will be measure using validated computerized tests which measure…
- Trial name
- NCT00582855
- Testing
- AQW051
- Where
- 12 sites in Canada, South Africa and 1 more
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline
Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.
This study aims to evaluate the efficacy of community-based early detection and targeted interventions, including stem cell therapy and wearable non-invasive brain-computer interface (BCI) devices, for Mild Cognitive Impairment…
- Conditions
- Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis
- Trial name
- MCITestCare (NCT07214974)
- Testing
- Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Noah Tech, Corp.
Alzheimer's Disease
ADNI: Alzheimer's Disease Neuroimaging Initiative
The purpose of this study is to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD).
- Trial name
- NCT00106899
- Testing
- Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Lumbar Puncture (LP)
- Where
- 59 sites in United States, Canada
- Volunteers
- 818 people, healthy volunteers welcome
- Sponsor
- Alzheimer's Disease Cooperative Study (ADCS)
Alzheimer Disease
Efficacy and Safety of Donepezil and Sodium Oligomannate in Patients With Mild to Moderate Alzheimer's Disease
Alzheimer's disease (AD) is the main cause of dementia. At present, AD is incurable. Cholinesterase inhibitors, especially donepezil, are the first choice for mild and moderate AD.
- Trial name
- NCT05114499
- Testing
- Donepezil, GV-971
- Volunteers
- 150 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Presbycusis, Bilateral, Alzheimer Disease 2 Due to Apoe4 Isoform
Hearing Aid and Individuals With Cognitive Disorders
This is a pilot study with the aim of evaluating the feasibility of the procedures of a future clinical trial that will help determine the impacts of hearing aid interventions on older patients with Alzheimer's Disease and…
- Conditions
- Presbycusis, Bilateral, Alzheimer Disease 2 Due to Apoe4 Isoform, Mild Cognitive Impairment
- Trial name
- NCT04049643
- Testing
- Audiologist-based fitting, Service-only Fitting, Device-only fitting
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Yu-Hsiang Wu
Alzheimer Disease
Open-label Extension for Phase 3 Clinical Trials of Simufilam
The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.
- Trial name
- NCT05575076
- Testing
- Simufilam
- Where
- 134 sites in United States, Australia and 3 more
- Volunteers
- 1,081 people
- Sponsor
- Cassava Sciences, Inc.
Older Adults (65 Years and Older), Cognitive Impairment, Mild
How Video Game Therapy Affects Thinking and Emotions in Older Adults With Cognitive Impairment
Golden Gamers Go is running a study together with Rey Juan Carlos University to better understand how videogames can help older adults, especially those with memory problems or cognitive decline.
- Trial name
- NCT07615647
- Testing
- Videogames masterclass, Therapy with videogames
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Golden Gamers Go SL
Mild Cognitive Impairment, Dementia Alzheimers
Protecting Alzheimer Caregivers Using Technology Through Staying Sharp
PROACTS is a Phase I/II study to assess the efficacy of AARP Staying Sharp online health program, focusing on the health of non-professional home-based caregivers of persons with Alzheimer's disease and related dementias (ADRD).
- Conditions
- Mild Cognitive Impairment, Dementia Alzheimers, Old Age; Dementia, Caregiver Burden
- Trial name
- PROACTS (NCT05260515)
- Testing
- Staying Sharp intervention
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Mild Cognitive Impairment (MCI), Amyloid Pathology
Using Light Therapy for Mild Cognitive Impairment
The goal of this clinical trial is to test whether transcranial photobiomodulation (tPBM), a non-invasive brain stimulation technique using near-infrared light, can improve brain blood flow regulation (neurovascular coupling) and…
- Trial name
- LTMC (NCT07651787)
- Testing
- Active Vielight Neuro RX-Duo device -Active transcranial photobiomodulation
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Oklahoma
Mild Cognitive Impairment
The Effect of Combination of Mediterranean Diet and Oleocanthal in Patients With Mild Cognitive Impairment
BACKGROUND: Mild cognitive impairment (MCI) constitutes a form of preclinical dementia and characterizes a cognitive decline that exceeds what is expected for one's age and education status, but at the same time does not fulfill…
- Trial name
- MeDi-SUPOL (NCT06705738)
- Testing
- SUPOL, Dietary Pattern: MeDi
- Where
- 2 sites in Greece
- Volunteers
- 200 people
- Sponsor
- Aristotle University Of Thessaloniki
Cognitive Impairment, Mild, Cognitive Dysfunction
MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients
Accumulating evidence indicates that inflammation is prominent both in the blood and central nervous system (CNS) of Alzheimer's disease (AD) patients.
- Conditions
- Cognitive Impairment, Mild, Cognitive Dysfunction, Amyloid Plaque, Neurodegeneration
- Trial name
- MCLENA-1 (NCT04032626)
- Testing
- Lenalidomide 10 mg
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Alzheimer Disease, Mild Cognitive Impairment
Noninvasive Brain Stimulation in Mild Cognitive Impairment and Dementia
The research objective of this study is to examine the efficacy of HD-tDCS to the preSMA/DACC region and its influence on verbal episodic memory in patients with MCI or dementia after 10 sessions of HD-tDCS.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Trial name
- NCT05270408
- Testing
- Active Transcranial direct current stimulation (STARStim 8)
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Texas Southwestern Medical Center
Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI)
Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance
Alzheimer's disease causes progressive memory and cognitive decline, driven in part by the buildup of a protein called β-amyloid in the brain.
- Trial name
- NCT07456462
- Testing
- MRI assessment and blood sample collection
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- IRCCS San Raffaele
Mild Cognitive Impairment, Dementia, Mild
Precision Medicine Approach for Early Dementia & Mild Cognitive Impairment
The goal of this clinical trial is to compare a precision medicine approach to the standard-of-care for people with mild cognitive impairment or early-stage dementia.
- Trial name
- EVANTHEA (NCT05894954)
- Testing
- Precision Medicine Approach, Hormones and Medications tailored to lab tests, combined with devices that support stress management and brain exercises, Standard-of-Care
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alzheimer's Prevention and Reversal Project, Inc.
Dementia, Alzheimer Disease
A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment
The purpose of this study is to evaluate the efficacy and safety of galantamine treatment in patients with mild cognitive impairment.
- Trial name
- NCT00236431
- Testing
- Galantamine hydrobromide
- Volunteers
- 1,063 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Mild Cognitive Impairment, Alzheimer Disease, Late Onset
Multimodal Assesment of Alzheimer Patients
The goal of this study is to learn more about the changes in the brains of patients with cognitive impairment (MCI) and Alzheimer's Disease (AD). The main questions the study aims to answer are: 1.
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Late Onset, Cognitive Impairment, Dementia
- Trial name
- MultiAD (NCT06448403)
- Testing
- MRI Scanning, 64-channel EEG, Polysomnography
- Where
- Norway
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Norwegian University of Science and Technology
Alzheimer's Disease
Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With Alzheimer's Disease
The primary objective of this Phase 2a study is to evaluate the maximal tolerated dose of ANAVEX2-73 in patients with AD in a repeated-dose administration scheme, with the secondary objectives being to explore the relationship…
- Trial name
- ANAVEX (NCT02244541)
- Testing
- ANAVEX2-73 Oral, ANAVEX2-73 Intravenous
- Where
- 5 sites in Australia
- Volunteers
- 32 people
- Sponsor
- Anavex Life Sciences Corp.